BTK and systemic lupus erythematosus: Surprisingly, Evobrutinib, a highly selective, orally administered BTK inhibitor, failed to show a treatment effect versus placebo in double-blind, randomized, phase 2 trials for SLE and multiple sclerosis [12,13].